Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 3Pancreatic Neoplasms 2Melanoma 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Neoplastic Cells, Circulating 1Myelodysplastic Syndromes 1Medulloblastoma 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Pancreatic Cancer 1

Interventions

Gemcitabine 406Oxaliplatin 131Fluorouracil 125130-nm albumin-bound paclitaxel 108Capecitabine 100Albumin-Bound Paclitaxel 90Leucovorin 88Irinotecan 87Radiotherapy 76Radiosurgery 64Taxes 63Cisplatin 56Erlotinib Hydrochloride 44Drug Therapy 42folfirinox 40Magnetic Resonance Spectroscopy 39pembrolizumab 35Blood Specimen Collection 33S 1 (combination) 31Pancreaticoduodenectomy 31Docetaxel 31Nivolumab 30Bevacizumab 30Biopsy 26Surgical Procedures, Operative 25Cyclophosphamide 25irinotecan sucrosofate 24Specimen Handling 24Radiation 22Standard of Care 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Pancreatic Neoplasms × Digoxin × Clear all
NCT04141995 2025-08-07

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

University of Nebraska

Phase 2 Terminated
11 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06030622 2024-04-19

C3

State University of New York - Downstate Medical Center

Phase 1/2 Unknown
25 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡